GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BLIS Technologies Ltd (NZSE:BLT) » Definitions » Financial Strength

BLIS Technologies (NZSE:BLT) Financial Strength : 0 (As of Mar. 2024)


View and export this data going back to 2001. Start your Free Trial

What is BLIS Technologies Financial Strength?

BLIS Technologies has the Financial Strength Rank of 0.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

BLIS Technologies's Interest Coverage for the quarter that ended in Mar. 2024 was 22.00. BLIS Technologies's debt to revenue ratio for the quarter that ended in Mar. 2024 was 0.03. As of today, BLIS Technologies's Altman Z-Score is 8.18.


Competitive Comparison of BLIS Technologies's Financial Strength

For the Biotechnology subindustry, BLIS Technologies's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BLIS Technologies's Financial Strength Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BLIS Technologies's Financial Strength distribution charts can be found below:

* The bar in red indicates where BLIS Technologies's Financial Strength falls into.



BLIS Technologies Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

BLIS Technologies's Interest Expense for the months ended in Mar. 2024 was NZ$-0.01 Mil. Its Operating Income for the months ended in Mar. 2024 was NZ$0.31 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was NZ$0.21 Mil.

BLIS Technologies's Interest Coverage for the quarter that ended in Mar. 2024 is

Interest Coverage=-1*Operating Income (Q: Mar. 2024 )/Interest Expense (Q: Mar. 2024 )
=-1*0.308/-0.014
=22.00

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

BLIS Technologies's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is

Debt to Revenue Ratio=Total Debt (Q: Mar. 2024 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.177 + 0.212) / 12.38
=0.03

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

BLIS Technologies has a Z-score of 8.18, indicating it is in Safe Zones. This implies the Z-Score is strong.

Good Sign:

Altman Z-score of 8.18 is strong.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BLIS Technologies  (NZSE:BLT) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

BLIS Technologies has the Financial Strength Rank of 0.


BLIS Technologies Financial Strength Related Terms

Thank you for viewing the detailed overview of BLIS Technologies's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


BLIS Technologies (NZSE:BLT) Business Description

Traded in Other Exchanges
N/A
Address
442 Moray Place, Ground Floor, Dunedin, OTA, NZL, 9016
BLIS Technologies Ltd is engaged in developing oral probiotics. The company markets two strains of probiotic bacteria BLIS K12, BLIS Q24, and BLIS M18 both of which occur naturally in the oral cavity. Its product portfolio consists of probiotic serum, Teeth and gums lozenge, fresh breath lozenge, and immune lozenge. Geographically, the company derives a majority of its revenue from EMEA (Europe, the Middle East, and Africa).

BLIS Technologies (NZSE:BLT) Headlines

From GuruFocus

Blount International Inc. (BLT) CEO Joshua L Collins buys 5,000 Shares

By GuruFocus Research GuruFocus Editor 06-17-2010

Blount International Inc. (BLT) CEO International Inc Blount buys 10,000 Shares

By GuruFocus Research GuruFocus Editor 10-01-2009

John Rogers Trims Stake in Blount International

By Kyle Ferguson Kyle Ferguson 04-18-2016

John Rogers Increases Stake in Blount International

By Tiziano Frateschi Tiziano Frateschi 04-13-2015

John Rogers' Recent Trades

By Tiziano Frateschi Tiziano Frateschi 04-06-2016

John Rogers Comments on Blount Intl Inc.

By Holly LaFon Holly LaFon 01-22-2016

Blount International Inc. (BLT) CEO Joshua L Collins buys 10,000 Shares

By GuruFocus Research GuruFocus Editor 10-13-2009